Pharmacokinetics of sunitinib in hemodialysis

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 190-192

  Izzedine, Hassan ^a   Etienne Grimaldi, M C ^b   Renee N ^b   Vignot, S ^a   Milano, G ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; DRUG METABOLITE; SU 12662; SUNITINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CASE REPORT; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LETTER; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; PREVALENCE; PRIORITY JOURNAL; SKIN DISCOLORATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

EID: 58949086801     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn626     Document Type: Letter

References (8)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005; 23: 202-212.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
6. Peces R, Martinez-Ara J, Miguel JL et al. Renal cell carcinoma co-existent with other renal disease: Clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant 2004; 19: 2789-2796.
7. Ishikawa I. Present status of renal cell carcinoma in dialysis patients in Japan: Questionnaire study in 2002. Nephron Clin Pract 2004; 97: c11-c16.
8. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.